Navigation Links
Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor Ian Meredith, M.D., Monash Medical Centre, Melbourne, Australia, on Tuesday presented positive nine-month results from the Medtronic RESOLUTE clinical trial at the EuroPCR meeting in Barcelona, Spain, with data showing a low number of adverse cardiac events and no protocol-defined stent thrombosis. The next-generation Medtronic (NYSE:MDT) Endeavor(R) Resolute drug-eluting stent system with new BioLinx(TM) polymer is designed to address the special needs of patients who have complex medical conditions and is engineered to match the duration of drug delivery with the longer healing duration often required by these patients.

In clinical results at nine months, the Endeavor RESOLUTE trial showed no Target Lesion Revascularization (TLR), no Target Vessel Revascularization (TVR) and a Major Adverse Cardiac Event (MACE) rate of just 7.0%. Of the trial's 130 patients, 129 (99.2%) received clinical follow-up, and 95 had angiographic follow-up. In-stent late lumen loss, the study's primary endpoint, was 0.22 mm, while in-segment late loss was 0.12 mm. In-stent Angiographic Binary Restenosis (ABR) was 1.0% percent and in-segment ABR was 2.1%.

"What is most impressive about these results is that they occurred in a patient population with complex and challenging characteristics," said Dr. Meredith, the principal investigator of the trial, noting that the average lesion length in the RESOLUTE trial was 15.5 mm and nearly 82% of enrolled patients were classified as having challenging B2/C lesions. "The RESOLUTE trial enrolled a high percentage of patients with lesions that are difficult to treat, including small vessels and long lesions, and these results are extremely promising. Zotarolimus continues to be a very potent drug in preventing restenosis while the new BioLinx polymer appears to be delivering the drug as intended."

Endeavor Resolute leverage
'"/>




Page: 1 2 3

Related medicine technology :

1. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
2. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
3. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:6/1/2015)... 1, 2015 Nevro Corp. (NYSE: NVRO ... innovative evidence-based solutions for the treatment of chronic pain, ... offering of its common stock consisting of 1,475,506 shares ... be sold by certain of its stockholders. In addition, ... to purchase up to an additional 590,202 shares of ...
(Date:6/1/2015)... , June 1, 2015 NEOVIA ONCOLOGY ... engaged in the development and commercialization of novel, ... it has met with the U.S. Food and ... filing of an Investigational New Drug (IND) application ... a result of the meeting, Neovia has clarified ...
(Date:6/1/2015)... June 1, 2015 Novel t ... drive growth , says   GBI Research ... (NSCLC) treatment market will be driven primarily by the introduction ... treatment settings, which either replace or combine with generic chemotherapies. ... Non-Small Cell Lung Cancer Market to 2020 - ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Neovia Oncology Announces First IND Meeting 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3
... Genomic Health , Inc. (Nasdaq: GHDX ... Financial Officer, will present at the 31st Annual Canaccord ... 2011 at 11:30 a.m. Eastern Time (ET).   ... of the presentation, visit the Investor Relations section of ...
... 2011 It,s back-to-school season and for many families, ... To view the multimedia assets associated with ... (Photo: http://photos.prnewswire.com/prnh/20110804/MM45457 ) Each ... U.S. are infested with this common, six-legged critter that ...
Cached Medicine Technology:Genomic Health to Present at the Canaccord Genuity Growth Conference 2Head Lice Returns to School: Five Tips to Avoid Panic and Worry 2
(Date:6/1/2015)... (PRWEB) June 01, 2015 More than 22 ... summer months when school is out and they lose access ... Month and America’s dairy farmers and milk companies are on ... need with The Great American Milk Drive. , In ... provided in the school cafeteria for the bulk of their ...
(Date:6/1/2015)... June 01, 2015 Northridge dentist ... now offering patients a promotion on Invisalign for a ... Invisalign treatment is reduced to $3,700. Patients can find ... complimentary consultation and discuss the extent of correction they ... cannot be combined with any other offer. , ...
(Date:6/1/2015)... Listen to Volvo’s Director of Connectivity Strategy, ... more granular data to create better customer oriented services. ... in Josep Celaya Gonzalez, CIO at MAPFRE, and Silvan ... automotive insurer, MAPFRE are well versed in capturing complex ... the driver. Award winning start-up ParkTAG offer an exciting ...
(Date:6/1/2015)... June 01, 2015 Hexagon Geospatial is ... is a new cloud-based subscription service that provides on-demand ... software. , Both ERDAS IMAGINE and ... Producer Online, which offers a subscription model for delivering ... need to be able to quickly and easily access ...
(Date:6/1/2015)... 2015 The session, entitled “Building the ... vice president of Elektrobit Automotive Americas, senior representatives ... it will be moderated by Andy Gryc of CX3 ... and complexity of in-vehicle software in connected vehicles and ... and how the wider ecosystem can fit into new ...
Breaking Medicine News(10 mins):Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:Northridge Dentists, Drs. Michel Elyson and Ramin Assili, are Now Offering a Limited Time Promotion on Invisalign 2Health News:Complimentary Webinar: Volvo, MAPFRE and Award Winning Start-Up discuss new Frontier of In-Car Services 2Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 2Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 3Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 2Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 3
... Sept. 3 Endo Pharmaceuticals (Nasdaq: ENDP ) ... the treatment of a distinct form of bladder cancer. VALSTAR ... Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the ... be associated with unacceptable medical risks. VALSTAR represents a ...
... owners to warning signs of PTSD, experts say , THURSDAY, ... was unaware that she was racing dangerously down the freeway ... nose nudge her elbow. , She immediately slowed down. , ... warning her that her anxiety levels were rising, a dangerous ...
... , Briefing is the first ... , WASHINGTON, Sept. 3 The following is ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090325/DC89081LOGO ) , ... Innovation will host a breakfast briefing on Capitol Hill titled "Education ...
... , EMERYVILLE, Calif., Sept. 3 Bionovo, Inc. (Nasdaq: ... from the phase 2 clinical trial of their lead drug candidate for ... Society for Gynecology (EGS) in Rome, Italy. , ... the safety and efficacy of two doses of Menerba versus placebo. The ...
... WASHINGTON, Sept. 3 The International Medical Interpreters ... building the organization,s international structure. The IMIA is proud ... Representative for Brazil. A medical interpreter trained in the ... now undergoing a Masters Program at Santa Catarina Federal ...
... , , ... and Drug Administration,s quest to dramatically reduce Salmonella-related food poisoning, ... country,s largest shell egg pasteurizer, opened a new state-of-the-art plant ... to eggs free from dangerous egg-related Salmonella-enteritidis. , , ...
Cached Medicine News:Health News:Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer 2Health News:Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer 3Health News:Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer 4Health News:Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer 5Health News:Service Dogs Help Traumatized Veterans Heal 2Health News:Service Dogs Help Traumatized Veterans Heal 3Health News:Council for American Medical Innovation to Host Capitol Hill Breakfast Briefing on Education and Immigration: The Building Blocks of Innovation 2Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 2Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 3Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 4Health News:IMIA Interpreter Association Appoints Brazil Representative 2Health News:National Pasteurized Eggs Increases Access to Safe Pasteurized Shell Eggs With New Plant Opening During September's National Food Safety Education Month 2
Each handle is designed to fit a specific trephine size....
20 GA TITANIUM RETINAL FORCEPS...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
Medicine Products: